Verdine’s FogPharma to bring lead cell-permeable peptide into clinic with $107M series C

FogPharma will use its venBio-led $107 million series C round to bring its lead program, a cell-permeable CTNNB1 antagonist, into the clinic for cancer.

The company, helmed by Chairman, President and CEO Greg Verdine, will also continue to build its pipeline of cell-penetrating mini-proteins against other recalcitrant targets using its Helicon platform, which aims to design candidates that combine the targeting specificity of antibodies with the cell penetration capabilities of small molecules. ...